Understanding Astrocyte Dysfunction: A Path Toward Treating Alexander Disease

Alexander Disease is a devastating genetic condition with no cure. Primarily affecting children, this rare disease damages the brain's white matter, leaving patients and their families in desperate need of new treatment options. While scientists know the disease is caused by mutations in a gene called GFAP, a significant mystery remains: in the brain, GFAP is only found in a specialized type of cell known as an astrocyte. It is not yet fully understood how mutations in an astrocyte-specific gene lead to such widespread white matter damage.

To address this critical gap in the field, Benjamin L.L. Clayton, PhD, an Assistant Professor in the Department of Genetics and Genome Sciences and the Institute for Glia Sciences at Case Western Reserve University (CWRU) School of Medicine, has launched a new investigative project. Dr. Clayton, a current CADRC REC scholar, is conducting this work through the Clayton Lab with the support of a two-year research grant from the End Alexander Disease Foundation, running from 2026 through 2028.

With this funding, Dr. Clayton’s team is working to understand how GFAP mutations disrupt normal gene activity in astrocytes, how these disruptions contribute to astrocyte pathology, and—crucially—how to restore normal function to these cells.

By uncovering the mechanisms that drive astrocyte dysfunction, this research has the potential to reveal new therapeutic targets, not only for Alexander Disease but potentially for other neurological conditions in which astrocytes play a central role. The long-term goal is to identify new strategies for reducing the damage caused by these mutations, bringing us closer to potential treatments for those affected by this condition.

Dr. Benjamin L.L. Clayton